Your browser doesn't support javascript.
loading
Cyclin-dependent kinase 12 is a drug target for visceral leishmaniasis.
Wyllie, Susan; Thomas, Michael; Patterson, Stephen; Crouch, Sabrinia; De Rycker, Manu; Lowe, Rhiannon; Gresham, Stephanie; Urbaniak, Michael D; Otto, Thomas D; Stojanovski, Laste; Simeons, Frederick R C; Manthri, Sujatha; MacLean, Lorna M; Zuccotto, Fabio; Homeyer, Nadine; Pflaumer, Hannah; Boesche, Markus; Sastry, Lalitha; Connolly, Paul; Albrecht, Sebastian; Berriman, Matt; Drewes, Gerard; Gray, David W; Ghidelli-Disse, Sonja; Dixon, Susan; Fiandor, Jose M; Wyatt, Paul G; Ferguson, Michael A J; Fairlamb, Alan H; Miles, Timothy J; Read, Kevin D; Gilbert, Ian H.
Afiliación
  • Wyllie S; Drug Discovery Unit, Wellcome Centre for Anti-Infectives Research, Division of Biological Chemistry and Drug Discovery, School of Life Sciences, University of Dundee, Dundee, UK.
  • Thomas M; Drug Discovery Unit, Wellcome Centre for Anti-Infectives Research, Division of Biological Chemistry and Drug Discovery, School of Life Sciences, University of Dundee, Dundee, UK.
  • Patterson S; Drug Discovery Unit, Wellcome Centre for Anti-Infectives Research, Division of Biological Chemistry and Drug Discovery, School of Life Sciences, University of Dundee, Dundee, UK.
  • Crouch S; Global Health R&D, GlaxoSmithKline, Tres Cantos, Spain.
  • De Rycker M; Drug Discovery Unit, Wellcome Centre for Anti-Infectives Research, Division of Biological Chemistry and Drug Discovery, School of Life Sciences, University of Dundee, Dundee, UK.
  • Lowe R; David Jack Centre for R&D, GlaxoSmithKline, Ware, UK.
  • Gresham S; David Jack Centre for R&D, GlaxoSmithKline, Ware, UK.
  • Urbaniak MD; Drug Discovery Unit, Wellcome Centre for Anti-Infectives Research, Division of Biological Chemistry and Drug Discovery, School of Life Sciences, University of Dundee, Dundee, UK.
  • Otto TD; Division of Biomedical and Life Sciences, Faculty of Health and Medicine, Lancaster University, Lancaster, UK.
  • Stojanovski L; Wellcome Sanger Institute, Cambridge, UK.
  • Simeons FRC; Centre of Immunobiology, Institute of Infection, Immunity & Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, UK.
  • Manthri S; Drug Discovery Unit, Wellcome Centre for Anti-Infectives Research, Division of Biological Chemistry and Drug Discovery, School of Life Sciences, University of Dundee, Dundee, UK.
  • MacLean LM; Drug Discovery Unit, Wellcome Centre for Anti-Infectives Research, Division of Biological Chemistry and Drug Discovery, School of Life Sciences, University of Dundee, Dundee, UK.
  • Zuccotto F; Drug Discovery Unit, Wellcome Centre for Anti-Infectives Research, Division of Biological Chemistry and Drug Discovery, School of Life Sciences, University of Dundee, Dundee, UK.
  • Homeyer N; Drug Discovery Unit, Wellcome Centre for Anti-Infectives Research, Division of Biological Chemistry and Drug Discovery, School of Life Sciences, University of Dundee, Dundee, UK.
  • Pflaumer H; Drug Discovery Unit, Wellcome Centre for Anti-Infectives Research, Division of Biological Chemistry and Drug Discovery, School of Life Sciences, University of Dundee, Dundee, UK.
  • Boesche M; Drug Discovery Unit, Wellcome Centre for Anti-Infectives Research, Division of Biological Chemistry and Drug Discovery, School of Life Sciences, University of Dundee, Dundee, UK.
  • Sastry L; Cellzome GmbH, A GlaxoSmithKline Company, Heidelberg, Germany.
  • Connolly P; Cellzome GmbH, A GlaxoSmithKline Company, Heidelberg, Germany.
  • Albrecht S; Drug Discovery Unit, Wellcome Centre for Anti-Infectives Research, Division of Biological Chemistry and Drug Discovery, School of Life Sciences, University of Dundee, Dundee, UK.
  • Berriman M; GlaxoSmithKline, New Frontiers Science Park, Harlow, UK.
  • Drewes G; Drug Discovery Unit, Wellcome Centre for Anti-Infectives Research, Division of Biological Chemistry and Drug Discovery, School of Life Sciences, University of Dundee, Dundee, UK.
  • Gray DW; Wellcome Sanger Institute, Cambridge, UK.
  • Ghidelli-Disse S; Cellzome GmbH, A GlaxoSmithKline Company, Heidelberg, Germany.
  • Dixon S; Drug Discovery Unit, Wellcome Centre for Anti-Infectives Research, Division of Biological Chemistry and Drug Discovery, School of Life Sciences, University of Dundee, Dundee, UK.
  • Fiandor JM; Cellzome GmbH, A GlaxoSmithKline Company, Heidelberg, Germany.
  • Wyatt PG; Global Health R&D, GlaxoSmithKline, Stockley Park West, Uxbridge, UK.
  • Ferguson MAJ; Global Health R&D, GlaxoSmithKline, Tres Cantos, Spain.
  • Fairlamb AH; Drug Discovery Unit, Wellcome Centre for Anti-Infectives Research, Division of Biological Chemistry and Drug Discovery, School of Life Sciences, University of Dundee, Dundee, UK.
  • Miles TJ; Drug Discovery Unit, Wellcome Centre for Anti-Infectives Research, Division of Biological Chemistry and Drug Discovery, School of Life Sciences, University of Dundee, Dundee, UK.
  • Read KD; Drug Discovery Unit, Wellcome Centre for Anti-Infectives Research, Division of Biological Chemistry and Drug Discovery, School of Life Sciences, University of Dundee, Dundee, UK.
  • Gilbert IH; Global Health R&D, GlaxoSmithKline, Tres Cantos, Spain. tim.j.miles@gsk.com.
Nature ; 560(7717): 192-197, 2018 08.
Article en En | MEDLINE | ID: mdl-30046105

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Pirazoles / Pirimidinas / Leishmania donovani / Quinasas Ciclina-Dependientes / Terapia Molecular Dirigida / Leishmaniasis Visceral Tipo de estudio: Prognostic_studies Límite: Animals / Humans Idioma: En Revista: Nature Año: 2018 Tipo del documento: Article País de afiliación: Reino Unido

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Pirazoles / Pirimidinas / Leishmania donovani / Quinasas Ciclina-Dependientes / Terapia Molecular Dirigida / Leishmaniasis Visceral Tipo de estudio: Prognostic_studies Límite: Animals / Humans Idioma: En Revista: Nature Año: 2018 Tipo del documento: Article País de afiliación: Reino Unido
...